John S. McBride
CIK: 0001618251
Associated companies
Transaction History
| ELDN | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 | View on chart |
| ELDN | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart
Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.